Author(s): Kalyanam Bharathi, Flavio J D Souza, Chandana C, Vishwanath B A

Email(s): Kalyanam.bharathi@gmail.com

DOI: 10.52711/2321-5836.2025.00020   

Address: Kalyanam Bharathi1*, Flavio J D Souza2, Chandana C3, Vishwanath B A4
1Associate Professor, Aditya Bangalore Institute of Pharmacy Education and Research, Rajiv Gandhi University of Health Sciences, Yelahanka, Bengaluru, 560064 Karnataka, India.
2,3ll Year M. Pharmacy, Department of Pharmacology, Aditya Bangalore Institute of Pharmacy Education and Research, Rajiv Gandhi University of Health Sciences, Yelahanka, Bengaluru, 560064 Karnataka, India.
4Professor, Aditya Bangalore Institute of Pharmacy Education and Research, Rajiv Gandhi University of Health Sciences,Yelahanka, Bengaluru, 560064 Karnataka, India.
*Corresponding Author

Published In:   Volume - 17,      Issue - 2,     Year - 2025


ABSTRACT:
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily associated with memory loss and cognitive decline. Despite significant advances in understanding its pathophysiology, particularly since its initial description by Alois Alzheimer in 1907, effective disease-modifying treatments remain elusive. The disease's development is influenced by several factors, including amyloid-beta accumulation, tau hyperphosphorylation, and cholinergic dysfunction, leading to neuronal degeneration. Emerging evidence also highlights the dopaminergic system's role in AD, with dopaminergic dysfunction contributing to memory impairments and non-cognitive symptoms even in early stages. The vascular hypothesis has garnered attention, suggesting a link between cardiovascular disease and AD, emphasizing vascular pathology as a significant risk factor for cognitive decline. Moreover, there is growing recognition of the heterogeneity in AD incidence and prevalence across different populations, with lower rates observed in certain Asian countries compared to Western nations. This variability is influenced by factors such as age, genetics, and lifestyle, as well as the challenges of standardized dementia assessments in developing regions. Additionally, biomarkers in cerebrospinal fluid and neuroimaging techniques, such as PET scans, have become essential tools in diagnosing AD and monitoring its progression, particularly through the detection of amyloid plaques and neurofibrillary tangles. Understanding the complex interplay of these factors is crucial for developing effective therapeutic strategies. The future of AD research lies in unravelling the intricate molecular mechanisms underlying its pathology and identifying potential targets for intervention.


Cite this article:
Kalyanam Bharathi, Flavio J D Souza, Chandana C, Vishwanath B A. Molecular Targets of Alzheimer’s Disease Treatment. Research Journal of Pharmacology and Pharmacodynamics.2025;17(2):121-0. doi: 10.52711/2321-5836.2025.00020

Cite(Electronic):
Kalyanam Bharathi, Flavio J D Souza, Chandana C, Vishwanath B A. Molecular Targets of Alzheimer’s Disease Treatment. Research Journal of Pharmacology and Pharmacodynamics.2025;17(2):121-0. doi: 10.52711/2321-5836.2025.00020   Available on: https://rjppd.org/AbstractView.aspx?PID=2025-17-2-7


REFERENCE:
1.    Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, Hofman A. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam studies. BMJ. 1995 Apr 15; 310(6985): 970-3. doi: 10.1136/bmj.310.6985.970.
2.    Thanvi B., Robinson T. Sporadic cerebral amyloid angiopathy—an important cause of cerebral haemorrhage in older people. Age Ageing. 2006; 35: 565–571. 10.1093/ageing/afl108
3.    Wang X., Michaelis M. L., Michaelis E. K. Functional genomics of brain aging and Alzheimers disease: focus on selective neuronal vulnerability. Curr. Genomics. 2010; 11: 618–633. 54.2174/138920210793360943.
4.    NIH National Institute on Aging (NIA). NIA scientists and other experts review this content to ensure it is accurate and up to date.   2017
5.    Martorana A, Koch G. Is dopamine involved in Alzheimer's disease? Frontiers in Aging Neuroscience. 2014; 6: 252.
6.    Bienias JL, Beckett LA, Bennett DA, Wilson RS, Evans DA. Design of the Chicago Health and Aging Project (CHAP). J Alzheimers Dis. 2003; 5: 349–355
7.    Eisenmenger LB, Peret A, Famakin BM, Spahic A, Roberts GS, Bockholt JH, Johnson KM, Paulsen JS. Vascular contributions to Alzheimer's disease. Translational Research. 2023 Apr 1; 254: 41-53
8.    Golde TE, Petrucelli L, Lewis J. Targeting Aβ and tau in Alzheimer's disease, an early interim report. Experimental Neurology. 2010 Jun 1; 223(2): 252-66.
9.    Kumari KN, Jeyabalan S, Rajangam J, Gopinathan N, Ramakrishnan SR, Reddy VJ. Neuroprotective Potential of Total Extract of Ulva Lactuca: An In vitro study. Research Journal of Pharmacy and Technology. 2023; 16(12): 5948-53.
10.    Lopez JA, González HM, Léger GC. Alzheimer's disease. Handbook of Clinical Neurology. 2019 Jan 1; 167: 231-55.
11.    Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences. 1993 Mar 1; 90(5): 1977-81.
12.    Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences. 2000 Mar 14; 97(6): 2892-7.
13.    Cruchaga C, Chakraverty S, Mayo K, Vallania FL, Mitra RD, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PloS one. 2012 Feb 1; 7(2): e31039
14.    Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimer's & Dementia. 2013 Jan 1; 9(1): E1-6.
15.    Peng J, Wang W, Song Q, Hou J, Jin H, Qin X, Yuan Z, Wei Y, Shu Z. 18F-FDG-PET Radiomics Based on White Matter Predicts the Progression of Mild Cognitive Impairment to Alzheimer Disease: A Machine Learning Study. Academic Radiology. 2023 Sep 1; 30(9): 1874-84.
16.    Wu W, Ji Y, Wang Z, Wu X, Li J, Gu F, Chen Z, Wang Z. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. European Journal of Medical Research. 2023 Nov 28; 28(1): 544.
17.    Sweeney MD, Sagare AP, Zlokovic BV. Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. Journal of Cerebral Blood Flow & Metabolism. 2015 Jul; 35(7): 1055-68.
18.    Pais MV, Forlenza OV, Diniz BS. Plasma biomarkers of Alzheimer’s disease: a review of available assays, recent developments, and implications for clinical practice. Journal of Alzheimer's Disease Reports. 2023 May 3(Preprint): 1-26.
19.    McGirr S, Venegas C, Swaminathan A. Alzheimers disease: A brief review. Journal of Experimental Neurology. 2020 Jul 29; 1(3): 89-98.
20.    Mathuranath PS, George A, Ranjith N, Justus S, Kumar MS, Menon R, Sarma PS, Verghese J. Incidence of Alzheimer′ s disease in India: A 10 years follow-up study. Neurology India. 2012 Nov 1; 60(6): 625-30.
21.    Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends (Doctoral dissertation, Alzheimer's Disease International).
22.    Cornutiu G. The epidemiological scale of Alzheimer’s disease. Journal of Clinical Medicine Research. 2015 Sep; 7(9): 657.
23.    Qiu C, Kivipelto M, Von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues in Clinical Neuroscience. 2009 Jun 30; 11(2): 111-28.
24.    MCKHANN G. Report of the NINCDS-ADRDA work group under the auspices of department of health and human service task force on Alzheimer's disease. Neurology. 1984; 34:939-44.
25.    Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1980 May; 7(5): 486-8.
26.    Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992 Mar; 42(3): 473
27.    Breslow NE. The design and analysis of cohort studies. Statistical Methods in Cancer Research. 1987; 2.
28.    Efron B. Logistic regression, survival analysis, and the Kaplan-Meier curve. Journal of the American Statistical Association. 1988 Jun 1; 83(402): 414-25
29.    Kumar A, Singh A. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological Reports. 2015 Apr 1; 67(2): 195-203.
30.    Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Annals of Indian Academy of Neurology. 2008 Jan 1; 11(1): 13-9.
31.    Liu Z, Zhang A, Sun H, Han Y, Kong L, Wang X. Two decades of new drug discovery and development for Alzheimer's disease. RSC Advances. 2017; 7(10): 6046-58.
32.    Mohamed T, Shakeri A, Rao PP. Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry. European Journal of Medicinal Chemistry. 2016 May 4; 113: 258-72.
33.    Prakash A, Dhaliwal GK, Kumar P, Majeed AB. Brain biometals and Alzheimer's disease–boon or bane? International Journal of Neuroscience. 2017 Feb 1; 127(2): 99-108.
34.    Sultzer DL, Marder SR. Older brains are different: brain–behavior studies and their CLinical UtiLity. The American Journal of Geriatric Psychiatry. 2017 Jan 1; 25(1): 11-2.
35.    Chase TN, Farlow MR, Clarence-Smith K. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease. Neurotherapeutics. 2017 Apr 1; 14(2): 405-16.
36.    Steenland K, Goldstein FC, Levey A, Wharton W. A meta-analysis of Alzheimer’s disease incidence and prevalence comparing African-Americans and Caucasians. Journal of Alzheimer's Disease. 2016 Jan 1; 50(1): 71-6.
37.    Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992 Apr 10; 256(5054): 184-5.
38.    Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016 Jun; 8(6): 595-608.
39.    Jadhav RP, Kengar MD, Narule OV, Koli VW, Kumbhar SB. A review on Alzheimer's Disease (AD) and its herbal treatment of Alzheimer's Disease. Asian Journal of Research in Pharmaceutical Science. 2019; 9(2): 112-22.
40.    Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Annals of Indian Academy of Neurology. 2008 Jan 1; 11(1): 13-9
41.    Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O’Neil JP. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain. 2017 Dec 1; 140(12): 3286-300
42.    Nawghare SM, Shrirao AV, Chandewar AV. Pharmacological Evaluation of Amaranthus viridis Linn leaves Extract for Anti Alzheimer’s Activity in Rat Models. Research Journal of Pharmacology and Pharmacodynamics. 2024 Sep 2; 16(3): 161-7.
43.    Pal T, Das M. Review of Alzheimer’s Disease’s Animal Model with it’s Pathophysiology and Drug Discovery.
44.    Prakash A, Dhaliwal GK, Kumar P, Majeed AB. Brain biometals and Alzheimer's disease–boon or bane? International Journal of Neuroscience. 2017 Feb 1; 127(2): 99-108
45.    Sultzer DL, Marder SR. Older brains are different: brain–behavior studies and their CLinical UtiLity. The American Journal of Geriatric Psychiatry. 2017 Jan 1; 25(1): 11-2.
46.    Chase TN, Farlow MR, Clarence-Smith K. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease. Neurotherapeutics. 2017 Apr 1; 14(2): 405-16.
47.    Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018 Jul 1; 141(7): 1917-33.
48.    Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992 Apr 10; 256(5054): 184-5.
49.    Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016 Jun; 8(6): 595-608.
50.    Twohig D, Nielsen HM. α-synuclein in the pathophysiology of Alzheimer’s disease. Molecular Neurodegeneration. 2019 Jun 11; 14(1): 23
51.    Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. Journal of Alzheimer's Disease. 2014 Jan 1; 42(s4): S421-9.
52.    Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Molecular Neurodegeneration. 2017 Dec; 12: 1-21.
53.    Blennow K. A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurology and Therapy. 2017 Jul; 6: 15-24.
54.    Lashley T, Schott JM, Weston P, Murray CE, Wellington H, Keshavan A, Foti SC, Foiani M, Toombs J, Rohrer JD, Heslegrave A. Molecular biomarkers of Alzheimer's disease: progress and prospects. Disease Models and Mechanisms. 2018 May 1; 11(5): 31781
55.    Tate BA, Mathews PM. Targeting the role of the endosome in the pathophysiology of Alzheimer's disease: a strategy for treatment. Science of Aging Knowledge Environment. 2006 Jun 28; 2006(10): re2.
56.    Islam M, Ramanjaneyulu J, Babu D, Hoque M, Swamy VB. Studies on memory enhancing property of bravobol-a polyherbal formulation in experimentally induced alzheimers disease in experimental animals. Asian Journal of Research in Pharmaceutical Science. 2015; 5(2):103-10.

Recomonded Articles:

Research Journal of Pharmacology and Pharmacodynamics (RJPPD) is an international, peer-reviewed journal....... Read more >>>

RNI: Not Available                     
DOI: 10.5958 2321-5836 

Journal Policies & Information




Recent Articles




Tags